Formycon Announces Health Canada Approval Of Ranibizumab Biosimilar

Product Is Already Launched Across US, Europe And MENA

 
• By Chloe Kent

Formycon has announced the approval of its biosimilar ranibizumab by Health Canada, with commercial launch by Teva expected to begin in Q1 next year.

Businessman giving thumbs up in front of Canadian flag
Commercial launch is expected during Q1 of 2024 • Source: Shutterstock

More from Biosimilars

More from Products